TAF1A: A Potential Drug Target and Biomarker for Fibrosis and Inherited Disabilities

Target Name: TAF1A

NCBI ID: G9015

TAF1A

Other Name(s): TATA box-binding protein-associated factor 1A | TAF1A variant 1 | TATA-box binding protein associated factor, RNA polymerase I subunit A | Transcription initiation factor SL1/TIF-IB subunit A | TBP-associated factor 1A | TATA box binding protein (TBP)-associated factor, RNA polymerase I, A, 48kD | TATA box binding protein (TBP)-associated factor, RNA polymerase I, A, 48kDa | TATA box-binding protein-associated factor RNA polymerase I subunit A (isoform 1) | TATA box binding protein (TBP)-associated factor, RNA polymerase I, A, 48kDa, transcript variant 1 | TAFI48 | transcription initiation factor SL1/TIF-IB subunit A | MGC:17061 | TATA box-binding protein-associated factor RNA polymerase I subunit A | TATA-box binding protein associated factor, RNA polymerase I subunit A, transcript variant 2 | TATA box-binding protein-associated factor RNA polymerase I subunit A (isoform 2) | RNA polymerase I-specific TBP-associated factor 48 kDa | TATA-box binding protein associated factor, RNA polymerase I subunit A, transcript variant 3 | RAFI48 | Transcription factor SL1 | SL1 | TAF1A variant 3 | TAF1A_HUMAN | SL1, 48kD subunit | TATA-box binding protein associated factor, RNA polymerase I, A | transcription factor SL1 | TAF1A variant 2

TAF1A: A Potential Drug Target and Biomarker for Fibrosis and Inherited Disabilities

Introduction

Fibrosis is a complex biological process that involves the progressive growth and accumulation of extracellular matrix (ECM) components, leading to the development of various diseases, including cancer, heart failure, and diabetes. The TATA box-binding protein-associated factor 1A (TAF1A ) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for fibrosis and other inherited disabilities.

TAF1A: A protein that plays a crucial role in gene regulation

TAF1A is a member of the TATA box-binding protein family, which are known for their ability to interact with specific DNA sequences to regulate gene expression. TAF1A is unique, as it has been shown to interact not only with DNA but also with RNA. This interaction between TAF1A and RNA molecules is critical for its function in gene regulation.

TAF1A is highly expressed in various tissues and cells, including tissues derived from the skin, gut, heart, and liver. It has been shown to play a role in regulating gene expression in various biological processes, including cell growth, differentiation, and inflammation.

TAF1A as a drug target: Potential therapeutic strategies

The therapeutic potential strategies for TAF1A are vast, as its involvement in gene regulation makes it an attractive target for a variety of diseases. Here are some of the most promising targets for TAF1A:

1.Fibrosis
TAF1A has been shown to be involved in the regulation of fibrosis, a complex biological process that involves the excessive accumulation of extracellular matrix components in tissues, leading to the development of fibrotic diseases. Studies have shown that TAF1A plays a role in the regulation of fibroblast growth and the production of extracellular matrix components, making it a potential target for the treatment of fibrosis.
2. Inflammation
TAF1A is involved in the regulation of inflammatory responses, and its expression has been shown to be associated with various inflammatory diseases, including heart failure, cancer, and diabetes. Therefore, TAF1A may be a potential target for the development of anti-inflammatory therapies.
3. Development and aging
TAF1A has been shown to be involved in the regulation of cellular processes that are important for development and aging. Its expression has been shown to be associated with the production of telomeres, a crucial component of chromosome stability that protects against the effects of aging. Therefore, TAF1A may be a potential target for therapies aimed at preventing or treating age-related diseases.

TAF1A as a biomarker: Diagnostic and predictive tools

TAF1A has also been shown to be a potential biomarker for various diseases, including fibrosis, cancer, and cardiovascular diseases. Its expression has been shown to be associated with the severity of these diseases, making it a promising tool for diagnostic purposes.

In addition, TAF1A levels have also been shown to be associated with certain predictive factors for disease, such as the risk of heart failure and the likelihood of developing certain cancers. This makes TAF1A a promising tool for the development of personalized medicine approaches.

Conclusion

TAF1A is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for fibrosis and other inherited disabilities. Its interaction with DNA and RNA molecules and its role in gene regulation make it an attractive target for therapeutic strategies aimed at preventing or treating a variety of diseases. Further research is needed to fully understand the functions of TAF1A and its potential as a drug and biomarker.

Protein Name: TATA-box Binding Protein Associated Factor, RNA Polymerase I Subunit A

Functions: Component of the transcription factor SL1/TIF-IB complex, which is involved in the assembly of the PIC (pre-initiation complex) during RNA polymerase I-dependent transcription. The rate of PIC formation probably is primarily dependent on the rate of association of SL1/TIF-IB with the rDNA promoter. SL1/TIF-IB is involved in stabilization of nucleolar transcription factor 1/UBTF on rDNA. Formation of SL1/TIF-IB excludes the association of TBP with TFIID subunits

The "TAF1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAF1A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets